Clinical and immune changes after Tixagevimab/Cilgavimab treatment in immune-weak patients with long COVID-related ME/CFS and ongoing spike protein in the blood

Persistent circulating SARS-CoV-2 spike protein may contribute to long-COVID pathophysiology.

• The role of spike protein in long-COVID is still under investigation.
• Administration of spike-targeting monoclonal antibodies may influence spike protein concentrations.
• Changes in autonomic receptor autoantibodies could occur following treatment with these antibodies.
• The relationship between monoclonal antibody treatment and clinical outcomes remains uncertain.

Simplified